Clinical trials
Locally Advanced Lung Carcinoma clinical trials
Below are recruiting locally advanced lung carcinoma clinical trials, each written for real people, not researchers. We’re tracking 549 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05456256RecruitingPhase 2
LP-300 plus chemo for lung cancer in never-smokers
This Phase 2 trial tests LP-300 with carboplatin and pemetrexed to treat advanced lung adenocarcinoma in people who have never smoked. It may help shrink tumors and slow the disease in a specific genetic group of lung cancer.
Beverly Hills, CaliforniaAges 18 years+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT05172245RecruitingPhase 1
Testing a new drug added to chemoradiation for head and neck cancer
This study tests whether adding a new targeted drug called ipatasertib to standard chemoradiation can improve treatment for people with locally advanced head and neck cancer. Ipatasertib may help block a protein that helps cancer grow, possibly making the standard therapy more effective.
Tampa, FloridaAges 18 years+ - NCT05136196RecruitingPhase 2
Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
Phoenix, ArizonaAges 18 years+ - NCT05098210RecruitingPhase 1
Personalized vaccine made from your tumor’s new immune targets
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
Seattle, WashingtonAges 18 years+ - NCT05085496RecruitingPhase 1
Radiation plus atezolizumab for advanced skin cancer
This Phase 1 trial studies adding atezolizumab (an immune therapy) to radiation for people with hard-to-remove or borderline-resectable cutaneous squamous cell carcinoma (cSCC). The goal is to see whether this combination can better control the cancer and whether the treatment is safe.
Duarte, CaliforniaAges 18 years+ - NCT05136846RecruitingPhase 1
Papaverine with chemoradiation for stage II–III lung cancer
This early-phase trial tests whether adding papaverine to standard chemoradiation can improve treatment for stage II–III non-small cell lung cancer (and some limited stage IV cases). It aims to see if the combination is safe and tolerable while targeting the cancer with radiation and chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT05010109Recruiting
Testing heart safety and fitness during lung cancer chemoradiation
This study looks at how lung cancer treatment affects the heart and whether a “walking test” and blood tests can track heart fitness and injury. It may help by improving how cancer therapy is planned and monitored for heart safety.
Houston, TexasAges 18 years+ - NCT04771520RecruitingPhase 2
Avapritinib for tumors with specific KIT or PDGFRA changes
This Phase 2 trial studies avapritinib, a targeted medicine, for people whose cancer has specific KIT or PDGFRA genetic changes. It may help shrink or slow growth of certain advanced cancers, including some brain tumors, when standard treatments have not worked or for specific glioblastoma cases.
Houston, TexasAges 18 years+ - NCT04749108RecruitingPhase 2/Phase 3
Tailored treatment for locally advanced rectal cancer after FOLFIRINOX
This trial studies a more customized treatment plan for people with locally advanced rectal (bowel) cancer after they receive FOLFIRINOX chemotherapy. It aims to reduce tumor spread risk and improve outcomes by tailoring the next steps based on scan details and your health status.
Marseille, Bouches Du RhôneAges 18 years+ - NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Birmingham, AlabamaAges 18 years+ - NCT04606446RecruitingPhase 2
Study drug for ER-positive, HER2-negative cancers after treatment
This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.
Scottsdale, ArizonaAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Studying a new drug for cancers with a specific TP53 change
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
Irvine, CaliforniaAges 12 years+ - NCT03191149RecruitingPhase 2
Osimertinib for lung cancer with an EGFR exon 20 change
This Phase 2 study tests osimertinib (a targeted lung cancer pill) in people with advanced non-small cell lung cancer (NSCLC) whose tumors have an EGFR exon 20 insertion. It aims to see how well osimertinib works for this specific EGFR mutation and how safe it is.
Anchorage, AlaskaAges 18 years+ - NCT02133196RecruitingPhase 2
T-cell treatment for lung cancer that has spread
This Phase 2 study tests a T-cell–based immunotherapy for people with metastatic non-small cell lung cancer that has grown despite prior treatment. It may help your immune system recognize and fight your cancer using cells made from your tumor.
Bethesda, MarylandAges 18–72 - NCT07309276RecruitingPhase 2
Study of JS212 for advanced lung cancer
This trial tests a new drug called JS212 combined with other treatments for people with advanced or spreading lung cancer. It aims to see if the combination can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Scottsdale, ArizonaAges 18 years+ - NCT07006727RecruitingPhase 1
Study of a new drug for advanced DLL3-positive solid tumors
This trial tests an experimental treatment for several types of advanced cancer that have stopped responding to standard therapy. The drug targets a protein called DLL3 found on some tumor cells, which may help slow or stop tumor growth.
Iowa City, IowaAges 18–100 - NCT06339619RecruitingPhase 2
Combination immunotherapy for advanced esophageal cancer after prior treatment
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
Guangzhou, GuangdongAges 18–75 - NCT06222489RecruitingPhase 2
HER3 PET scan for advanced EGFR-mutant lung cancer
This study uses a special PET/CT scan to measure a protein called HER3 in your tumors. The scan uses a radioactive version of the drug patritumab deruxtecan (HER3-DXd). This test may help doctors understand how much HER3 is in your cancer and decide if HER3-targeted therapy could work for you.
Amsterdam, North HollandAges 18 years+ - NCT05925491RecruitingPhase 2
Pembrolizumab for locally advanced nasal cavity cancer
This trial tests pembrolizumab (an immune therapy) for locally advanced sinonasal cancer that can still be cured with local treatments. It aims to improve outcomes by helping your immune system better fight the tumor.
Pavia, LombardyAges 18 years+ - NCT06823427RecruitingPhase 2
9MW2821 with or without immunotherapy for advanced urothelial cancer
This trial tests a combination of an investigational drug (9MW2821) with an immunotherapy (toripalimab) against 9MW2821 alone for people with advanced urothelial cancer who have not yet received any systemic treatment. The goal is to see if the combination works better than the single drug.
Changsha, HunanAges 18–80 - NCT07274852RecruitingPhase 1
Study of a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
Chengdu, SichuanAges 18 years+ - NCT07263919RecruitingPhase 2
Chemo plus cadonilimab before surgery for esophageal cancer
This trial tests adding cadonilimab to standard chemotherapy before surgery for esophageal cancer that can be removed. It aims to see if this combination helps shrink the tumor and improve outcomes.
Xi'anAges 18–75
Hear when a new Locally Advanced Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced lung carcinoma?
- Yes. Clin2 currently lists 549 recruiting locally advanced lung carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced lung carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced lung carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Lung Non-Small Cell Carcinoma
- Locally Advanced Rectal Carcinoma
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced Lung Non-Small Cell Carcinoma
- Locally Advanced Nasopharyngeal Carcinoma
- Locally Advanced Cervical Carcinoma
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.